Changde-based drug maker, renamed under the CSPC group, selling branded heart, cancer, bone-joint and digestive injections and Chinese-medicine capsules.
Changde-based drug maker, renamed under the CSPC group, selling branded heart, cancer, bone-joint and digestive injections and Chinese-medicine capsules.
Sells branded prescription injections and Chinese-medicine capsules mainly to hospitals, using a mix of distributor recruitment and its own sales team, with several products held exclusive nationally. A court-led restructuring finished in early 2026, and the company now carries the CSPC group name in its title and logo.
Moat: narrow (regulatory licence, brand). Several nationally exclusive Chinese-medicine products on the national reimbursement list; now under the CSPC group name.
Headquarters: Changde, China · Employees: 463
Size CSPC Hunan Jingfeng Pharmaceutical (000908.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.85B, the 1251st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥4.74 on 18 Nov 2026.
Performance Over six months the shares fell 37.8%, against -4.7% for the median peer and -20.0% for the China market (cap-weighted) — lowest of 21 in its peer set.
Growth Revenue grew 5.3% over the last twelve months (peer median +10.0%); the operating margin is -18.3% (peer median 15.0%).
Valuation It trades at 25.8× enterprise value to sales against a peer median of 3.5× (most expensive of 21).
Capital Return on invested capital runs 17.1 points below its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥414M | CN¥375M | CN¥412M | CN¥650M | CN¥833M |
| Revenue growth | — | -9% | -37% | -22% | — |
| Gross profit | CN¥270M | CN¥215M | CN¥240M | CN¥421M | CN¥599M |
| EBITDA | n/a | -CN¥16.2M | CN¥11.1M | -CN¥56.9M | CN¥42.8M |
| Net income | -CN¥34.8M | -CN¥80.9M | CN¥152M | -CN¥236M | -CN¥123M |
| Free cash flow | -CN¥159M | CN¥54.8M | -CN¥6.93M | CN¥24.6M | CN¥110M |
| Capital expenditure | CN¥63.9M | CN¥4.57M | CN¥1.38M | CN¥10.4M | CN¥13.5M |
| Total debt | CN¥6.73M | CN¥286M | CN¥466M | CN¥601M | CN¥608M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| CSPC Hunan Jingfeng Pharmaceutical 000908.SZ | $1.85B | -38% | +5% | -18% | 25.8× | n/a |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | $45.7B | -13% | +6% | 27% | 8.0× | 13.4% |
| Tasly Pharmaceutical 600535.SS | $3.19B | -2% | -4% | 19% | 2.2× | -7.5% |
| Shijiazhuang Yiling Pharmaceutical 002603.SZ | $3.83B | -7% | +32% | 21% | 2.9× | -3.9% |
| Shandong Buchang Pharmaceuticals 603858.SS | $2.25B | -7% | +4% | 10% | 1.5× | -2.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 000908.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -14.1% | +0.7% | 3rd lowest of 21 |
| 6-month return | -37.8% | -4.7% | lowest of 21 |
| Distance from 52-week high | -50.0% | -28.3% | 4th lowest of 21 |
| Revenue growth (TTM) | +5.3% | +10.0% | 9th lowest of 21 |
| Operating margin | -18.3% | 15.0% | 3rd lowest of 21 |
| EV / Sales | 25.8× | 3.5× | most expensive of 21 |
| ROIC minus cost of capital | -17.1 pp | +2.4 pp | 3rd lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| CSPC Hunan Jingfeng Pharmaceutical 000908.SZ | China | $1.85B | -38% | +5% | -18% | 25.8× | n/a | n/a |
| Dermapharm DMP.DE | Germany | $1.85B | -29% | +2% | 21% | 2.3× | -3.4% | +8.0% |
| Cohance Lifesciences COHANCE.NS | India | $1.87B | +7% | +14% | 2% | 8.6× | n/a | n/a |
| Tibet Rhodiola Pharmaceutical 600211.SS | China | $1.87B | -8% | +13% | 27% | 3.4× | -1.2% | +16.7% |
| Shenyang Xingqi Pharmaceutical 300573.SZ | China | $1.83B | -25% | +17% | 33% | 4.2× | 5.4% | +29.1% |
| Anhui Anke Biotechnology (Group) 300009.SZ | China | $1.88B | -12% | -9% | 30% | 4.8× | 8.0% | +9.3% |
| Pfizer PFIZER.NS | India | $1.88B | -20% | +12% | 34% | 5.5× | 11.2% | +2.4% |
| Guobang Pharma 605507.SS | China | $1.82B | -6% | +3% | 12% | 1.9× | -6.0% | +7.4% |
| China National Accord Medicines 000028.SZ | China | $1.81B | -3% | 0% | 2% | 0.3× | -9.5% | +4.2% |
| Zymeworks ZYME | United States | $1.81B | +5% | +98% | 17% | 8.9× | n/a | n/a |
| Ultragenyx Pharmaceutical RARE | United States | $1.81B | -24% | +16% | -64% | 3.7× | n/a | n/a |
| Qingdao Baheal Medical 301015.SZ | China | $1.81B | +2% | -6% | 8% | 2.0× | 10.1% | +5.0% |
| Alivus Life Sciences ALIVUS.NS | India | $1.90B | +36% | +8% | 31% | 6.3× | 20.1% | +6.2% |
| Shenzhen Hepalink Pharmaceutical 002399.SZ | China | $1.80B | -12% | -6% | 8% | 2.1× | -0.7% | +0.5% |
| United Laboratories International 3933.HK | Hong Kong | $1.80B | -20% | -13% | 5% | 0.6× | 1.2% | +7.8% |
| Shilpa Medicare SHILPAMED.NS | India | $1.91B | +94% | +37% | 21% | 10.1× | n/a | n/a |
| Eton Pharmaceuticals ETON | United States | $1.79B | +226% | +101% | 29% | 12.4× | 21.9% | +359.6% |
| Harbin Pharmaceutical 600664.SS | China | $1.78B | +32% | +2% | 5% | 0.7× | -5.3% | +8.2% |
| Grand Pharmaceutical 0512.HK | Hong Kong | $1.93B | -25% | +7% | 13% | 1.5× | 1.2% | +14.1% |
| Tsumura & 4540.T | Japan | $1.93B | +6% | +13% | 18% | 2.0× | n/a | n/a |
| Agios Pharmaceuticals AGIO | United States | $1.78B | +4% | +214% | -298% | 8.3× | n/a | n/a |